Kapogiannis D

References (3)

Title : A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase - Tzieras_2026_Neurotherapeutics_23_e00918
Author(s) : Tzieras I , Manolopoulos A , Tweedie D , Luo W , Maccecchini M , Egan JM , Greig NH , Kapogiannis D
Ref : Neurotherapeutics , 23 :e00918 , 2026
Abstract :
PubMedSearch : Tzieras_2026_Neurotherapeutics_23_e00918
PubMedID: 42127455
Gene_locus related to this paper: human-BCHE

Title : Synaptic proteins in neuron-derived extracellular vesicles as biomarkers for Alzheimer's disease: novel methodology and clinical proof of concept - Eitan_2023_Extracell.Vesicles.Circ.Nucl.Acids_4_133
Author(s) : Eitan E , Thornton-Wells T , Elgart K , Erden E , Gershun E , Levine A , Volpert O , Azadeh M , Smith DG , Kapogiannis D
Ref : Extracell Vesicles Circ Nucl Acids , 4 :133 , 2023
Abstract :
PubMedSearch : Eitan_2023_Extracell.Vesicles.Circ.Nucl.Acids_4_133
PubMedID: 37842184

Title : Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease - Goetzl_2018_FASEB.J_32_888
Author(s) : Goetzl EJ , Abner EL , Jicha GA , Kapogiannis D , Schwartz JB
Ref : FASEB Journal , 32 :888 , 2018
Abstract :
PubMedSearch : Goetzl_2018_FASEB.J_32_888
PubMedID: 29025866